Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Bcwm LLC

Bcwm LLC lifted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 19,993 shares of the medical equipment provider’s stock after buying an additional 1,209 shares during the period. Bcwm LLC’s holdings in Zimmer Biomet were worth $2,170,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of ZBH. OLD Point Trust & Financial Services N A acquired a new position in Zimmer Biomet in the 4th quarter valued at $26,000. Ables Iannone Moore & Associates Inc. purchased a new stake in shares of Zimmer Biomet in the fourth quarter valued at $30,000. Crewe Advisors LLC acquired a new position in Zimmer Biomet in the first quarter valued at $31,000. Family Firm Inc. purchased a new position in shares of Zimmer Biomet during the 2nd quarter worth about $33,000. Finally, J.Safra Asset Management Corp raised its stake in Zimmer Biomet by 712.1% during the first quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 235 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

ZBH has been the subject of several research analyst reports. Evercore ISI restated an “in-line” rating and set a $113.00 price target on shares of Zimmer Biomet in a research note on Thursday, September 5th. Citigroup decreased their price objective on shares of Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. Truist Financial reissued a “hold” rating and issued a $112.00 target price (down previously from $117.00) on shares of Zimmer Biomet in a research note on Friday. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research report on Thursday, August 8th. Finally, Royal Bank of Canada reduced their target price on shares of Zimmer Biomet from $140.00 to $130.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and an average price target of $125.44.

Zimmer Biomet Stock Up 1.1 %

Zimmer Biomet stock opened at $106.26 on Monday. The firm has a market capitalization of $21.64 billion, a P/E ratio of 23.00, a P/E/G ratio of 1.92 and a beta of 1.02. The company has a 50-day simple moving average of $109.90 and a 200-day simple moving average of $116.03. Zimmer Biomet Holdings, Inc. has a one year low of $102.00 and a one year high of $133.90. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.63 and a current ratio of 1.29.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 EPS for the quarter, beating the consensus estimate of $1.99 by $0.02. The company had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. Zimmer Biomet’s revenue was up 3.9% compared to the same quarter last year. During the same quarter last year, the business earned $1.82 earnings per share. As a group, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.02 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.90%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.